Cargando…

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulte...

Descripción completa

Detalles Bibliográficos
Autores principales: Homet Moreno, B, Ribas, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453674/
https://www.ncbi.nlm.nih.gov/pubmed/25856776
http://dx.doi.org/10.1038/bjc.2015.124
_version_ 1782374498969845760
author Homet Moreno, B
Ribas, A
author_facet Homet Moreno, B
Ribas, A
author_sort Homet Moreno, B
collection PubMed
description Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers of patients with melanoma, lung, kidney, bladder and triple-negative breast cancer, as well as in chemotherapy-refractory Hodgkin disease. There is already evidence from at least one randomised trial that anti-PD-1 therapy is superior to chemotherapy in the treatment of patients with metastatic melanoma, and two anti-PD-1 antibodies, pembrolizumab and nivolumab, have been approved by the US Food and Drug Administration for the treatment of patients previously treated for metastatic melanoma. It is anticipated that approvals by drug regulatory bodies will be forthcoming in several cancers in the next months.
format Online
Article
Text
id pubmed-4453674
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44536742015-06-09 Anti-programmed cell death protein-1/ligand-1 therapy in different cancers Homet Moreno, B Ribas, A Br J Cancer Minireview Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers of patients with melanoma, lung, kidney, bladder and triple-negative breast cancer, as well as in chemotherapy-refractory Hodgkin disease. There is already evidence from at least one randomised trial that anti-PD-1 therapy is superior to chemotherapy in the treatment of patients with metastatic melanoma, and two anti-PD-1 antibodies, pembrolizumab and nivolumab, have been approved by the US Food and Drug Administration for the treatment of patients previously treated for metastatic melanoma. It is anticipated that approvals by drug regulatory bodies will be forthcoming in several cancers in the next months. Nature Publishing Group 2015-04-28 2015-04-09 /pmc/articles/PMC4453674/ /pubmed/25856776 http://dx.doi.org/10.1038/bjc.2015.124 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Minireview
Homet Moreno, B
Ribas, A
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title_full Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title_fullStr Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title_full_unstemmed Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title_short Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
title_sort anti-programmed cell death protein-1/ligand-1 therapy in different cancers
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453674/
https://www.ncbi.nlm.nih.gov/pubmed/25856776
http://dx.doi.org/10.1038/bjc.2015.124
work_keys_str_mv AT hometmorenob antiprogrammedcelldeathprotein1ligand1therapyindifferentcancers
AT ribasa antiprogrammedcelldeathprotein1ligand1therapyindifferentcancers